Synaptogenix, Inc. (NASDAQ:SNPX) Short Interest Down 26.8% in February

Synaptogenix, Inc. (NASDAQ:SNPX) was the target of a large decline in short interest in February. As of February 28th, there was short interest totalling 21,800 shares, a decline of 26.8% from the February 13th total of 29,800 shares. Based on an average daily volume of 15,000 shares, the days-to-cover ratio is currently 1.5 days. Approximately 1.6% of the shares of the company are sold short.

Synaptogenix Stock Performance

Shares of NASDAQ:SNPX traded up $0.09 on Monday, reaching $2.81. 585 shares of the company’s stock were exchanged, compared to its average volume of 12,896. Synaptogenix has a twelve month low of $2.32 and a twelve month high of $6.22. The company has a fifty day moving average of $3.12 and a 200-day moving average of $3.08.

Institutional Trading of Synaptogenix

A hedge fund recently bought a new stake in Synaptogenix stock. Geode Capital Management LLC bought a new stake in Synaptogenix, Inc. (NASDAQ:SNPX) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 10,844 shares of the company’s stock, valued at approximately $39,000. Geode Capital Management LLC owned approximately 0.80% of Synaptogenix at the end of the most recent quarter. Institutional investors and hedge funds own 10.34% of the company’s stock.

Synaptogenix Company Profile

Synaptogenix, Inc operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. The company focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. It also evaluates therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease.